The European health care system is moving toward personalised, distributed, and home-based services. This is made possible via new and improved connected medical devices (MDs) and in vitro diagnostic devices connected to the internet (together, CMDs), and will benefit health care providers in terms of reduced cost (fewer hospital beds) and improved service. Patients will see improved quality of life in terms of reduced travel time and reduced stress via treatment at home or where they want it. However, for these benefits to be fully realised, the cybersecurity of CMDs needs to be ensured.
NEMECYS will benefit practitioners such as cybersecurity communities, MD manufacturers, CMD scenario system integrators and CMD scenario operators (e.g. health care providers), with downstream benefits to patients and the wider public, through more cost-effective and efficient care enabled via effective and streamlined cybersecurity.
NEMECYS helps practitioners to (1) comply with MD regulations; (2) to be able to apply proportionate MD cybersecurity (too little security risks exposure, too much is costly and can obstruct clinical care) and (3) build in cybersecurity by design for both MDs and the connected scenarios they operate in. This is achieved by (1) providing recommendations for best practice and guidelines for MD cybersecurity by design, along with compliance assurance tooling; (2) providing a risk-benefit scheme to address cybersecurity risk balanced with clinical benefit; and (3) providing a set of specific tools to address MD cybersecurity by design and their deployment in connected scenarios.
The NEMECYS team has cybersecurity risk experts, two hospitals who are already implementing IoT and remote care-based scenarios, three medical device manufacturers, major computer science research players and experienced systems integrators. This team is ideally placed to ensure that NEMECYS can enable practitioners to apply the right security at the right place, at low cost.
The NEMECYS consortium comprises 11 partners from 6 European countries (Norway, United Kingdom, Greece, Spain, Italy, Switzerland) and one partner from Israel.
- SINTEF AS [SINTEF, Project coordinator] (NORWAY)
- MODE SENSORS AS [Mode] (NORWAY)
- IBM ISRAEL – SCIENCE AND TECHNOLOGY LTD [IBM] (ISRAEL)
- Athens Technology Center S.A. [ATC] (GREECE)
- MARINA SALUD SA [MS] (SPAIN)
- OSPEDALE SAN RAFFAELE SRL [OSR] (ITALY)
- PANEPISTIMIO IOANNINON [UoI] (GREECE)
- INFORMATION CATALYST SL [IKS] (SPAIN)
- UNIVERSITY OF SOUTHAMPTON [UoS] (UK)
- INFORMATION CATALYST FOR ENTERPRISE LTD [ICE] (UK)
- PD NEUROTECHNOLOGY LTD [PDN] (UK)
- DEBIOTECH S.A. [DB] (SWITZERLAND)
ATC is the integration leader of the project and will orchestrate the delivery of the NEMECYS ecosystem that combines a variety of technological outcomes. ATC also leads the Dissemination, Exploitation and Outreach activities of the project.
The project started in January 2023 and will last for 36 months.
